Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches.
hadrontherapy
high risk prostate cancer
iPARP treatment
narrative review
personalized medicine
second-generation antiandrogens
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
06
2021
accepted:
13
07
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
Various definitions are currently in use to describe high-risk prostate cancer. This variety in definitions is important for patient counseling, since predicted outcomes depend on which classification is applied to identify patient's prostate cancer risk category. Historically, strategies for the treatment of localized high-risk prostate cancer comprise local approaches such as surgery and radiotherapy, as well as systemic approaches such as hormonal therapy. Nevertheless, since high-risk prostate cancer patients remain the group with higher-risk of treatment failure and mortality rates, nowadays, novel treatment strategies, comprising hypofractionated-radiotherapy, second-generation antiandrogens, and hadrontherapy, are being explored in order to improve their long-term oncological outcomes. This narrative review aims to report the current management of high-risk prostate cancer and to explore the future perspectives in this clinical setting.
Identifiants
pubmed: 34422672
doi: 10.3389/fonc.2021.732766
pmc: PMC8371196
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
732766Informations de copyright
Copyright © 2021 Marvaso, Corrao, Zaffaroni, Pepa, Augugliaro, Volpe, Musi, Luzzago, Mistretta, Verri, Cossu Rocca, Ferro, Petralia, Nolè, De Cobelli, Orecchia and Jereczek-Fossa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with one of the authors BJ.
Références
Eur Urol. 2017 Jan;71(1):37-43
pubmed: 27523595
Int J Clin Oncol. 2017 Aug;22(4):611-618
pubmed: 28508305
Nat Rev Urol. 2019 Sep;16(9):523-538
pubmed: 31346291
Pharmacol Ther. 2016 Apr;160:65-83
pubmed: 26896565
Cancers (Basel). 2020 Aug 31;12(9):
pubmed: 32878283
Cancers (Basel). 2018 Apr 10;10(4):
pubmed: 29642619
Ann Oncol. 2018 Aug 1;29(8):1784-1792
pubmed: 29767688
Radiother Oncol. 2020 Jun;147:92-98
pubmed: 32247206
Cancer. 2013 Sep 15;119(18):3287-94
pubmed: 23821578
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303
pubmed: 28463149
Drug Des Devel Ther. 2018 May 29;12:1501-1509
pubmed: 29881257
J Biol Chem. 2012 Feb 3;287(6):3777-87
pubmed: 22174412
Adv Radiat Oncol. 2019 Jul 16;4(4):668-673
pubmed: 31681864
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Cancers (Basel). 2020 Jun 25;12(6):
pubmed: 32630494
Br J Cancer. 2014 May 13;110(10):2389-95
pubmed: 24722181
BMC Cancer. 2018 Apr 2;18(1):354
pubmed: 29606109
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Eur Urol Focus. 2019 Jul;5(4):577-584
pubmed: 29221876
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
J Clin Oncol. 2021 Apr 10;39(11):1234-1242
pubmed: 33497252
Cancer J. 2009 Jul-Aug;15(4):306-11
pubmed: 19672147
Tumori. 2017 May 12;103(3):314-318
pubmed: 28009421
Cancer. 1997 Apr 1;79(7):1370-80
pubmed: 9083160
Front Oncol. 2016 Feb 12;6:23
pubmed: 26904502
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):715-22
pubmed: 24521685
Lancet. 2011 Dec 17;378(9809):2104-11
pubmed: 22056152
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):856-62
pubmed: 25936597
Cancer Res. 2012 May 1;72(9):2176-82
pubmed: 22411952
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):964-974
pubmed: 33186616
Lancet Oncol. 2011 May;12(5):451-9
pubmed: 21440505
Lancet Oncol. 2010 Nov;11(11):1066-73
pubmed: 20933466
BJU Int. 2019 Nov;124 Suppl 1:19-30
pubmed: 31507035
Nat Rev Clin Oncol. 2017 Aug;14(8):483-495
pubmed: 28290489
Scand J Urol. 2018 Oct - Dec;52(5-6):313-320
pubmed: 30585526
Prostate Cancer Prostatic Dis. 2007;10(1):82-6
pubmed: 16983394
Radiother Oncol. 2004 Dec;73(3):265-8
pubmed: 15588869
Clin Transl Radiat Oncol. 2020 Sep 01;25:22-28
pubmed: 32995575
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55
pubmed: 17531401
Prostate. 2018 Jan;78(1):64-75
pubmed: 29134684
Urol Oncol. 2020 Apr;38(4):184-190
pubmed: 31928867
Semin Surg Oncol. 2000 Jan-Feb;18(1):52-74
pubmed: 10617897
Cancer Sci. 2017 Dec;108(12):2422-2429
pubmed: 28921785
Lancet Oncol. 2018 Nov;19(11):1504-1515
pubmed: 30316827
Lancet Oncol. 2018 Jul;19(7):975-986
pubmed: 29880291
Lancet Oncol. 2015 Dec;16(16):1605-16
pubmed: 26522334
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-24
pubmed: 21324610
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Oncoscience. 2017 Apr 14;4(3-4):27-28
pubmed: 28540332
BMC Urol. 2019 May 6;19(1):33
pubmed: 31060606
Lancet. 2009 Jan 24;373(9660):301-8
pubmed: 19091394
Eur Urol Oncol. 2018 Jun;1(2):143-148
pubmed: 31100238
Cancer. 2019 Feb 1;125(3):391-397
pubmed: 30423193
Ther Adv Med Oncol. 2018 Jun 22;10:1758835918778483
pubmed: 29977351
Front Oncol. 2020 Feb 04;10:82
pubmed: 32117737
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59-65
pubmed: 30171229
JAMA. 2008 Jan 23;299(3):289-95
pubmed: 18212313
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Pract Radiat Oncol. 2018 Nov - Dec;8(6):354-360
pubmed: 30322661
Prostate Cancer Prostatic Dis. 2007;10(4):323-30
pubmed: 17563766
Cancer J. 2009 Jul-Aug;15(4):285-91
pubmed: 19672144
J Clin Oncol. 2008 Feb 1;26(4):585-91
pubmed: 18172188
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Eur Urol. 2018 Oct;74(4):432-441
pubmed: 29980331
Prostate. 2004 Feb 15;58(3):252-8
pubmed: 14743464
Eur Urol. 2020 May;77(5):614-627
pubmed: 32146018
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Cancers (Basel). 2019 Oct 18;11(10):
pubmed: 31635359
Mol Biol Cell. 2016 Jul 15;27(14):2145-8
pubmed: 27418635
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116
Int J Urol. 2012 Apr;19(4):296-305
pubmed: 22320843
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
BMC Cancer. 2020 Jan 30;20(1):75
pubmed: 32000716
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):685-91
pubmed: 18718725
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Cureus. 2017 Jul 10;9(7):e1453
pubmed: 28929037
J Clin Oncol. 2017 Jun 10;35(17):1891-1897
pubmed: 28355113